Security
Therapix Biosciences Ltd American Depositary Receipts - Sponsored · THXBY
THXBYOTCotherHistorical · closed Mar 22, 2017CIK 1611746Updated Oct 27, 2026
Name history
SciSparc Ltd./ADR · through Aug 27, 2021Therapix Biosciences Ltd. · through Jan 28, 2021
Current security for this SEC filerSPRC · NASDAQ
THXBY price & chart
Historical security
This listing closed Mar 22, 2017. Live provider charts are shown only for current listings.
Current security: SPRC
About the company
The Company, through its majority-owned subsidiary NeuroThera, engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera, is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer’s disease and agitation; and SCI- 210 for the treatment of autism spectrum disorder and status epilepticus. The Company, through NeuroThera, also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2024 · USDSource
Source
Source
cash flow · annual statements
| Line item | Q2 2018 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Profit or LossUSD | -1,214,000Source | -7,472,000Source | -5,883,000Source | -2,592,000Source | -5,789,000Source |
| Additional Financial Items | |||||
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableUSD | -50,000Source | 12,000Source | 55,000Source | 3,000Source | 170,000Source |
| AdjustmentsForIncreaseDecreaseInTradeAccountPayableUSD | -101,000Source | 25,000Source | -397,000Source | — | 353,000Source |
| AdjustmentsForSharebasedPaymentsUSD | 138,000Source | 569,000Source | 196,000Source | — | 43,000Source |
| GeneralAndAdministrativeExpenseUSD | 1,000,000Source | 4,526,000Source | 5,031,000Source | 6,509,000Source | 3,778,000Source |
| InterestPaidClassifiedAsFinancingActivitiesUSD | — | 8,000Source | 7,000Source | — | — |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | — | 54,000Source | 47,000Source | — | — |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesUSD | — | — | — | 9,005,000Source | 7,699,000Source |
| ProceedsFromIssuingSharesUSD | — | 6,255,000Source | — | — | — |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesUSD | — | — | — | 4,861,000Source | — |
income statement · annual statements
| Line item | Q2 2022 | Q2 2018 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | — |
| Selling, General and Administrative ExpenseUSD | — | — | — | 5,031,000Source | 6,509,000Source | 3,778,000Source |
| Total RevenueUSD | — | — | 1,306,000Source | 2,879,000Source | 1,347,000Source | — |
| Additional Financial Items | ||||||
| ApplicableTaxRatenumber | — | — | — | 0.23Source | 0.23Source | 0.23Source |
| BasicEarningsLossPerShareUSD per share | — | — | 26.94Source | 14.43Source | — | 2.83Source |
| DilutedEarningsLossPerShareUSD per share | — | — | 26.94Source | 14.43Source | — | — |
| EmployeeBenefitsExpenseUSD | — | — | 106,000Source | 105,000Source | 115,000Source | 98,000Source |
| FinanceCostsUSD | — | 1,000Source | 353,000Source | 1,055,000Source | 2,014,000Source | 21,000Source |
| FinanceIncomeUSD | — | 437,000Source | 612,000Source | 2,219,000Source | 7,832,000Source | — |
| GeneralAndAdministrativeExpenseUSD | — | 1,000,000Source | 4,526,000Source | 5,031,000Source | 6,509,000Source | 3,778,000Source |
| GrossProfitUSD | 10,210,000Source | — | 506,000Source | 2,196,000Source | 1,025,000Source | — |
| ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillUSD | — | — | 1,344,000Source | — | — | — |
| IncomeTaxExpenseContinuingOperationsUSD | — | — | -14,000Source | 22,000Source | 14,000Source | — |
| OtherIncomeUSD | — | — | 1,270,000Source | — | — | — |
| OtherOperatingIncomeExpenseUSD | — | — | — | — | -109,000Source | — |
| ProfitLossAttributableToNoncontrollingInterestsUSD | — | — | -1,188,000Source | -761,000Source | — | — |
| ProfitLossAttributableToOwnersOfParentUSD | — | — | -6,284,000Source | -5,122,000Source | 2,592,000Source | 5,789,000Source |
| ProfitLossBeforeTaxUSD | — | — | -7,486,000Source | -5,861,000Source | -2,578,000Source | — |
| ProfitLossFromOperatingActivitiesUSD | — | -1,650,000Source | -7,316,000Source | -6,815,000Source | -8,287,000Source | -5,768,000Source |
| ResearchAndDevelopmentExpenseUSD | — | 650,000Source | 1,707,000Source | 1,641,000Source | 2,803,000Source | 1,990,000Source |
| ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodUSD | — | — | -429,000Source | -210,000Source | -109,000Source | — |
Offerings
Registration 333-293533
Registration 333-293167
Filing attachments
ea031077601ex4-1.htm · 6-K · 2026-11-03
Exhibit 4.1 NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ SECURITIES ACT ”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO A…
Read attachment ↗ea031077601ex4-2.htm · 6-K · 2026-11-03
Exhibit 4.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL SELECTED B…
Read attachment ↗ea030941001ex99-1.htm · 6-K · 2026-10-23
Exhibit 99.1 SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome TEL AVIV, Israel, Oct. 22, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary, NeuroThera Labs Inc. (TSXV: NTLX) (“NeuroThera”), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, has achieved further progress in its U.S. Food …
Read attachment ↗ea030872201ex99-1.htm · 6-K · 2026-10-15
Exhibit 99.1 SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies TEL AVIV, Israel, Oct. 15, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that it will shift its strategic focus toward Agentic AI-powered technologies, including cybersecurity and finance technologies. Building on its previously announced decision on July 27, 2026 to target the Agentic AI market and the announc…
Read attachment ↗ea030793702ex99-1.htm · 6-K · 2026-10-07
Exhibit 99.1 SciSparc: Subsidiary NeuroThera Labs’ CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company’s Quantum Architecture TEL AVIV, Israel, Oct. 07, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) (“NeuroThera”), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous sys…
Read attachment ↗ea030686801ex99-1.htm · 6-K · 2026-09-30
Exhibit 99.1 SCISPARC LTD. INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2026 UNAUDITED INDEX Page Consolidated Statements of Financial Position 2-3 Consolidated Statements of Profit or Loss and Other Comprehensive Loss 4 Consolidated Statements of Changes in Equity (Deficit) 5-6 Consolidated Statements of Cash Flows …
Read attachment ↗